Estimation of interferon gamma and some inflammatory atherogenic biomarkers levels in obese coronary atherosclerotic patients
Keywords:Coronary atherosclerosis, Obesity, Proinflammatory marker, Interferon gamma
Background and objective: Coronary atherosclerosis is an inflammatory disease that may be caused by numerous factors. One of the most important factors is obesity; there are high concentrations of interferon gamma (IFN-γ) in obese patients. This study aimed to assess the levels of proinflammatory markers IFN-γ and high sensitive C- reactive protein (Hs-CRP) in obese coronary atherosclerotic patients and determine its correlation with lipid profiles.
Methods: The present case-control study was carried out between December 2017 and May 2018 in the Cardiac Center-Surgical Specialty Hospital in Erbil city. It included 49 coronary atherosclerotic patients, 25 males and 24 females, and 39 controls. The sera were subjected to estimate of some inflammatory biomarkers including IFN-γ, Hs-CRP, and lipid profile such as total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoproteins cholesterol (LDL-C) and very low- density lipoproteins (VLDL-C).
Results: Serum concentrations of IFN-γ and Hs-CRP in coronary atherosclerotic patients were increased significantly than controls (P = 0.031, P = 0.001), respectively. Indeed the same above results were seen in obese coronary atherosclerotic patients and controls than non-obese coronary atherosclerotic patients controls. The mean concentration of lipid profile in obese coronary atherosclerotic patients was decreased than non -obese coronary atherosclerotic patients and controls, with no significant differences (P ≥0.05). There was a weak negative significant correlation between IFN-γ and HDL-C in obese coronary atherosclerotic patients (r= -0.456; P = 0.040).
Conclusion: Proinflammatory cytokine as IFN-γ played a vital role in the pathophysiology of obese atherosclerotic patients in combination with Hs-CRP and LDL-C, which could be used as predictors for progressive the disease.
Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal 2015; 67(2):89–97.
Rocha VZ, Folco EJ, Sukhova G , Shimizu K, Gotsman I, Vernon AH, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008; 103(50):467–76.
Fatkhullina AR, Peshkova IO, Koltsova EK. The Role of cytokines in the development of atherosclerosis. J Biochemistry 2016; 81(11): 1358–70.
Harvey E, Ramji. Interferon-γ and atherosclerosis: Pro- or anti-atherogenic?. Cardiovasc Res 2005; 67(1):11–20.
Ilhan F, Kalkanli ST, 2015. Atherosclerosis and the role of immune cells. World J Clin Cases 2015; 3:345–52.
Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 2015; 31(2):177–83.
Sun S, Ji Y, Kersten S, Qi L. Mechanisms of inflammatory responses in obese adipose tissue. Annu Rev Nutr 2012; 32:261–86.
Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013; 20:678159.
Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84(4):1381–478.
World Health Organization. Obesity: Prevention and Managing The Global Eipedimic 2000. Technical Report Series no. 894.
Talavera-Garcia E, Delgado-Lista J, Garcia-Rios A, Delgado-Casado N, Gomez-Luna P, Gomez-Garduño A, et al. Influence of Obesity and Metabolic Disease on Carotid Atherosclerosis in Patients with Coronary Artery Disease (CordioPrev Study). PloS One 2016; 11(4):e0157213.
Salari A, Shakiba M, Mahdavi-Roshan M, Gholipour M, Naghshbandi M, Rajabi R. The association between various indices of obesity and severity of atherosclerosis in adults in the north of Iran. Medicine 2016; 95(50):e5670.
Roever LS, Resende ES, Diniz ALD, Penha-Silva N, Veloso FC, Casella-Filho A, et al. Abdominal Obesity and Association With Atherosclerosis Risk Factors: The Uberlândia Heart Study. Medicine 2016; 95(11):e1357.
Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 2010; 17(6):511–31.
Fairweather D. Sex differences in inflammation during atherosclerosis. Clinical Medicine Insights Cardiology 2015; 8(3):49–59.
Weidner G. Why do men get more heart disease than women? An international perspective. J of ACH 2000; 48(6):291–4.
Fernandez ML, Murillo AG. Postmenopausal Women Have Higher HDL and Decreased Incidence of Low HDL than Premenopausal Women with Metabolic Syndrome.Healthcare (Basel) 2016; 4(1):20.
Imes CC, Lewis FM. Family history of cardiovascular disease, perceived cardiovascular disease risk, and health-related behavior: a review of the literature. J Cardiovasc Nurs 2014; 29(2):108–29.
Ordovas JM. Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. Am J Clin Nutr 2009; 89(5):1509S–17.
Pandey AK, Blaha MJ, Sharma K, Rivera J, Budoff MJ, Blankstein R, et al. Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-EthnicStudyofAtherosclerosis(MESA). Atherosclerosis 2014; 232(2):369–76.
Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21(6):961–7.
Reardon CA, Lingaraju A, Schoenfelt KQ, Zhou G, Cui C, Jacobs-El H, et al. Obesity and Insulin Resistance Promote Atherosclerosis through an IFNγ-Regulated Macrophage Protein Network. Cell Rep 2018; 23(10):3021–30.
Zhang H, Potter BJ, Cao J-M, Zhang C. Interferon-gamma induced adipose tissue inflammation is linked to endothelial dysfunction in type 2 diabetic mice. Basic Res Cardiol 2011; 106(6):1135–45.
Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15(4):6184–223.
Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res 2017; 113(9):1009–23.
Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010; 201(5):289645.
Liang Y, Hou Y, Niu H, Lu M, Xue L, Sun Q. Correlation of high-sensitivity C-reactive protein and carotid plaques with coronary artery disease in elderly patients. Experimental and therapeutic medicine. 2015; 10(1):275–8.
Bhatti MS, Akbri MZ, Shakoor M. Lipid profile in obesity. JAMC 2001;13(1):31–3.
Haddad FH, Omari AA, Shamailah QM, Malkawi OM, Shehab AI, Mudabber HK, et al. Lipid profile in patients with coronary artery disease. Int J Sci Rep 2002; 23(9):1054–8.
Panousis CG, Zuckerman SH. Regulation of cholesterol distribution in macrophage-derived foam cells by interferon-gamma. J Lipid Res 2000; 41(1):75–83.
Liang K, Dong SR, Peng H. Serum levels and clinical significance of IFN-gamma and IL-10 in patients with coronary heart disease. European Review for Medical and Pharmacological Sciences 2016; 20(7):1339–43.
Ranjbaran H, Sokol SI, Gallo A, Eid RE, Iakimov AO, D’Alessio A, et al. An Inflammatory Pathway of IFN-γ Production in Coronary Atherosclerosis. J Immunol 2007; 178(1):592–604.
Feig JE, Feig JL, Dangas GD. The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications. Coron Artery Dis 2016; 27(7):592–603.
How to Cite
Copyright (c) 2020 Alia Talat Abdulrahman, Ruqaya Muhammed AL-Barzinji (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).